When a dose reduction is the correct response to a side effect

When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: tirzepatide, 22 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 11 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

Worth separating two things that the opening post runs together.

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

The honest answer is that it depends, and here is what it depends on.

Nothing to add, except that this is the answer I would give if asked.

Post #3 answers the question as asked. The question underneath it is different.

Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.

Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.

That holds for the case as described. Change the assumptions and it may not.

Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.

That is the version I use. It may not be the version that is correct.

Seconded. It reads as careful rather than confident, which is the right register.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

The confident version of this sentence would be wrong, so here is the hedged one.

Filing a mild objection to the consensus on dose reduction. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

Anyone who has looked at this more carefully, please correct the record.

Following this. I have the same question and no better information than the first post.